XERS

AI Memo

Xeris Biopharma

As of 2026-09-17/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

FY2026 revenue-guidance delivery • 2026-12-31

Base target: $10 / p=50% prob

Biggest risk

Gvoke revenue declined 4% year over year, SG&A rose 37% amid commercial expansion, R&D rose 32%, and the company remained loss-making. Execution must therefore convert higher spending into durable revenue and cash generation [#SEC-8K-2026-08-06].

Invalidation

Break below $6 or thesis failure.

What would change my mind?

Record quarterly revenue, 34% net-product-revenue growth, 81% Recorlev growth, an 86% gross margin, and tightened FY2026 revenue guidance support a cautiously positive commercial-execution thesis [#SEC-8K-2026-08-06].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-17

Base target

$10

p=50%

Bull target

$12

p=30%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Recorlev-led commercial momentum
Keveyis intellectual-property durability
Record quarterly revenue, 34% net-product-revenue growth, 81% Recorlev growth, an 86% gross margin, and tightened FY2026 revenue guidance support a cautiously positive commercial-execution thesis [#SEC-8K-2026-08-06].

BearKey bullets

Direct peer comparability, verified analyst revisions, post-release price attribution, and detailed pipeline milestone timing remain limited.
Gvoke revenue declined 4% year over year in the second quarter, indicating uneven performance across the portfolio [#SEC-8K-2026-08-06].
Recorlev contributes most of the reported growth, increasing sensitivity to patient demand, reimbursement, and commercial execution.

WatchKey bullets

FY2026 revenue-guidance delivery

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $10 (p=50%)

Target spread vs base: +29% / -39%

Scenario probabilities

Bull Target: $12 (p=30%)Base Target: $10 (p=50%)Bear Target: $6 (p=20%)

Commentary

Primary-source tone is constructive following strong second-quarter revenue growth, Recorlev momentum, improved gross margin, and tighter FY2026 guidance. However, verified post-release price attribution, analyst revisions, options skew, short interest, employee sentiment, and sufficient social coverage are unavailable; missing inputs are not treated as positive evidence. Low coverage and loose peers warrant a cautious monitoring stance.

As of 2026-09-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Recorlev-led commercial momentum
Keveyis intellectual-property durability

Scenarios

Bull Target (Scenario probability)

$12 / p=30% prob

Base Target (Scenario probability)

$10 / p=50% prob

Bear Target (Scenario probability)

$6 / p=20% prob

Analysis 2026-09-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.58

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
FY2026 revenue-guidance delivery
Management tightened FY2026 total-revenue guidance to $385–$390 million after reporting $92.1 million of second-quarter revenue. Achieving or exceeding that range would validate portfolio momentum; a miss would challenge current growth expectations [#SEC-8K-2026-08-06].
Prob 68.00% • Move 14.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Recorlev-led commercial momentum
2026-12-31
Second-quarter Recorlev revenue rose 81% year over year to approximately $56.8 million, driving 34% net-product-revenue growth. Continued patient demand and contribution from the expanded commercial organization could support second-half performance, while slower uptake would weaken the thesis [#SEC-8K-2026-08-06].
Prob 70% • Move 10% • Priced-in 65%

Long-term Catalysts

Months to a year

Keveyis intellectual-property durability
2039-12-31
Xeris received a USPTO Notice of Allowance for a Keveyis patent expected to extend protection through at least 2039. The potential benefit is a longer-duration commercial cash-flow stream, although patent issuance timing and competitive durability remain uncertain [#SEC-8K-2026-08-06].
Prob 65% • Move 8% • Priced-in 50%

Risks

Direct peer comparability, verified analyst revisions, post-release price attribution, and detailed pipeline milestone timing remain limited.
Gvoke revenue declined 4% year over year in the second quarter, indicating uneven performance across the portfolio [#SEC-8K-2026-08-06].
Recorlev contributes most of the reported growth, increasing sensitivity to patient demand, reimbursement, and commercial execution.
SG&A increased 37% and R&D increased 32% year over year; failure to generate sufficient incremental revenue could pressure profitability and cash generation [#SEC-8K-2026-08-06].
Several officers reported open-market sales from July through September 2026; Form 4 filings establish the transactions but not their motivation [#SEC-FORM4-2026-07-07] [#SEC-FORM4-2026-08-04] [#SEC-FORM4-2026-09-01].

Peers

Symbol	Summary
ABSI	Similar in market capitalization and sector classification, but its operating model is not established as directly comparable with Xeris's marketed-product portfolio; unsuitable as a primary valuation anchor.
MAZE	Similar-market-cap biopharma candidate, but the packet does not establish comparable commercial products, indications, revenue maturity, or risk profile.
TRAX	Same-sector and similar-market-cap candidate, but insufficient operating evidence supports direct comparison with Xeris.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-17

Loading AI feed…

Symbol

Summary

ABSI

Similar in market capitalization and sector classification, but its operating model is not established as directly comparable with Xeris's marketed-product portfolio; unsuitable as a primary valuation anchor.

MAZE

Similar-market-cap biopharma candidate, but the packet does not establish comparable commercial products, indications, revenue maturity, or risk profile.

TRAX

Same-sector and similar-market-cap candidate, but insufficient operating evidence supports direct comparison with Xeris.